ES2196007T3 - Especificidad para peptidos sinteticos de los anti-proteina basica de la mielina procedentes del liquido cefalorraquideo en esclerosis multiple. - Google Patents

Especificidad para peptidos sinteticos de los anti-proteina basica de la mielina procedentes del liquido cefalorraquideo en esclerosis multiple.

Info

Publication number
ES2196007T3
ES2196007T3 ES93908754T ES93908754T ES2196007T3 ES 2196007 T3 ES2196007 T3 ES 2196007T3 ES 93908754 T ES93908754 T ES 93908754T ES 93908754 T ES93908754 T ES 93908754T ES 2196007 T3 ES2196007 T3 ES 2196007T3
Authority
ES
Spain
Prior art keywords
synthetic peptides
mbp
protein
multiple sclerosis
waste
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93908754T
Other languages
English (en)
Inventor
Kenneth G Warren
Ingrid Catz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Alberta
Original Assignee
University of Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Alberta filed Critical University of Alberta
Application granted granted Critical
Publication of ES2196007T3 publication Critical patent/ES2196007T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PROTEINA DE LA MIELINA BASICA HUMANA (H-NBP) TIENE UN PESO MOLECULAR DE 18.5 KD Y CONTIENE 170 RESIDUOS DE AMINOACIDO. SE HAN PRODUCIDO LOS PEPTIDOS SINTETICOS QUE TIENEN UNA LONGITUD QUE OSCILA ENTRE 8 Y 25 RESIDUOS Y QUE CUBREN LA LONGITUD COMPLETA DE LA PROTEINA. SE HA HALLADO QUE LOS ANTICUERPOS PARA LA H-MBP (ANTI-MBP) SON NEUTRALIZADOS POR LOS PEPTIDOS SINTETICOS, QUE CUBREN LA H-MBP DESDE ALREDEDOR DEL RESIDUO (61) DEL AMINOACIDO HASTA ALREDEDOR DEL RESIDUO (106) DEL AMINOACIDO. LOS PEPTIDOS SINTETICOS, QUE CUBREN LOS TERMINALES TANTO DE AMINO (ENTRE LOS RESIDUOS 1 A 63) Y DE CARBOXIDO (ENTRE LOS RESIDUOS 117 Y 162) DE LA H-MBP NO NEUTRALIZAN LOS ANTIMBP PURIFICADOS. CONCORDANTEMENTE, DE LOS PEPTIDOS SINTETICOS SELECCIONADOS DE LA MBP PUEDE USARSE COMO TRATAMIENTO PARA LA ESCLEROSIS MULTIPLES NEUTRALIZANDO LOS ANTI-MBP.
ES93908754T 1991-10-22 1992-10-15 Especificidad para peptidos sinteticos de los anti-proteina basica de la mielina procedentes del liquido cefalorraquideo en esclerosis multiple. Expired - Lifetime ES2196007T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002053799A CA2053799C (en) 1991-10-22 1991-10-22 Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid

Publications (1)

Publication Number Publication Date
ES2196007T3 true ES2196007T3 (es) 2003-12-16

Family

ID=4148603

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93908754T Expired - Lifetime ES2196007T3 (es) 1991-10-22 1992-10-15 Especificidad para peptidos sinteticos de los anti-proteina basica de la mielina procedentes del liquido cefalorraquideo en esclerosis multiple.

Country Status (12)

Country Link
EP (1) EP0610446B1 (es)
AT (1) ATE236193T1 (es)
AU (1) AU2750092A (es)
CA (1) CA2053799C (es)
DE (1) DE69232987T2 (es)
DK (1) DK0610446T3 (es)
ES (1) ES2196007T3 (es)
FI (1) FI111050B (es)
NO (1) NO310513B1 (es)
NZ (1) NZ244807A (es)
RU (1) RU2121850C1 (es)
WO (1) WO1993008212A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817629A (en) * 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US6252040B1 (en) 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
BR9509438A (pt) * 1994-10-25 1997-12-23 Immulogic Pharma Corp Composições e tratamento para a esclerose múltipla
DE69525544T2 (de) 1994-11-18 2002-08-22 Neurocrine Biosciences, Inc. Peptidanaloga des menschlichen myelinbasischen proteins mit substitution in position 91 zur behandlung von multipler sklerose
US6379670B1 (en) 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6251396B1 (en) 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6329499B1 (en) 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
WO1996028470A2 (en) * 1995-03-09 1996-09-19 Neurocrine Biosciences, Inc. Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
CA2494338C (en) * 1997-04-04 2007-07-17 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
RU2244719C1 (ru) * 2003-07-29 2005-01-20 Терентьев Александр Александрович Композиция из пептидов, обладающая иммуномодуляторным свойством
RU2266297C1 (ru) * 2004-05-12 2005-12-20 Терентьев Александр Александрович Композиция из пептидов, обладающая иммунорегуляторным свойством
WO2005009455A1 (fr) * 2003-07-29 2005-02-03 Terentiev Alexandr Alexandrovi Composition de peptides presentant une propriete immunoregulatrice
EP1753455A2 (en) * 2004-06-04 2007-02-21 Genentech, Inc. Method for treating multiple sclerosis
WO2011046462A1 (en) * 2009-10-12 2011-04-21 Angport Limited Composition for treatment of multiple sclerosis
US9326773B2 (en) 2012-01-26 2016-05-03 Covidien Lp Surgical device including buttress material
EP4611796A1 (en) * 2022-11-01 2025-09-10 Universität Zürich Novel mbp peptides and their use in the treatment of multiple sclerosis

Also Published As

Publication number Publication date
DK0610446T3 (da) 2003-07-14
CA2053799A1 (en) 1993-04-23
NO310513B1 (no) 2001-07-16
EP0610446B1 (en) 2003-04-02
FI111050B (fi) 2003-05-30
DE69232987D1 (de) 2003-05-08
WO1993008212A1 (en) 1993-04-29
EP0610446A1 (en) 1994-08-17
ATE236193T1 (de) 2003-04-15
AU2750092A (en) 1993-05-21
NZ244807A (en) 1997-08-22
RU94027578A (ru) 1996-10-20
NO941415L (es) 1994-06-22
NO941415D0 (no) 1994-04-19
CA2053799C (en) 2002-03-12
FI941860L (fi) 1994-04-21
DE69232987T2 (de) 2004-01-29
FI941860A0 (fi) 1994-04-21
RU2121850C1 (ru) 1998-11-20

Similar Documents

Publication Publication Date Title
ES2170104T3 (es) Inhibidores de la produccion de proteinas de beta-amiloide.
ES2190653T3 (es) Productos de reaccion del acido hialuronico y de aminoacidos naturales y su utilizacion en composiciones cosmeticas y farmaceuticas.
ES2077666T3 (es) Proteina de union a fibronectina y su preparacion.
ES2178000T3 (es) Composiciones y metodos para tratar infecciones usando analogos de indolicidina.
ES2193145T3 (es) Proteinas procoagulants quimericas.
GT199700079A (es) Derivados triciclos sustituidos con fenilamino
ES2150983T3 (es) Productos proteicos bactericidas estables que incrementan la permeabilidad y composiciones farmaceuticas que los contienen.
ES2074042T3 (es) Exotoxina recombinante de pseudomonas construccion de una inmunotoxina activa con efectos secundarios menores.
ES2122958T3 (es) Utilizacion de una proteina bactericida/incrementando la permeabilidad o de analogos biologicamente activos de esta proteina para fabricar un medicamento para tratar las afecciones relacionadas con la endotoxina.
MX9205985A (es) Epitopes de las celulas t de los alergenos principales del genero dermatophagoides y composiciones farmaceuticas que los contienen.
MX9204685A (es) Secuencia de adn que codifica una proteina superficial externa (ospa) o derivado de la misma composicion de vacuna qe comprende tal proteina.
MX9207334A (es) Acidos nucleicos peptidicos y formulacion farma- ceutica que los contiene
ES2177636T3 (es) Utilizacion del agua empobrecida en deuterio en la preparacion de cosmeticos.
DE60032486D1 (de) Prion protein peptide und deren verwendung
AR003589A1 (es) Utilizacion de una cantidad eficaz de al menos un peptido en una composicion cosmetica o para la preparacion de un medicamento destinada paratratar la inflamacion, y un procedimiento de tratamiento cosmetico mediante una composicion cosmetica que contiene a dicho peptido.
DE69635582D1 (de) Diagnostika und behandlungen von peridontalen erkrankungen
DK0610446T3 (da) Syntetisk peptidspecificitet af antimyelin basic protein fra cerebrospinalvæske fra dissemineret sklerose
ES2194836T3 (es) Peptidos para su uso en vacunacion e induccion de anticuerpos neutralizantes contra el virus de la inmunodeficiencia humana.
DE69831257D1 (de) Histogranin peptide und deren analgetische verwendung
AR002742A1 (es) Proteina reguladora del tipo adiposo, procedimiento para producir dicha proteina, formulaciones farmaceuticas que la incluyen, molecula de adn aisladaque codifica dicha proteina, vector y celulas recombinantes que comprenden dicho adn
ES2103733T3 (es) Procedimiento para combatir el piojo de los peces.
BR9911917A (pt) Composições compreendendo análogos de gaba e cafeìna
IL69475A (en) Polypeptide having an action on the immunological system,processes for its isolation and purification,its protease cleavage products and pharmaceutical compositions containing them
AR246310A1 (es) Procedimiento para la preparacion de la cadena alfa- del receptor de la interleucina 5 humana, o partes del mismo, secuencia del adn, vector y celula hospedante.
ES2099322T3 (es) Composicion cosmetica para el tratamiento del foto-envejecimiento de la piel.